This multicenter, retrospective, observational study will evaluate the therapeutic effectiveness of a strategy of induction with Fuzeon (enfuvirtide) within an optimized regimen of antiretroviral drugs in patients with HIV-1 infection in routine clinical practice.
Study Type
OBSERVATIONAL
Enrollment
58
Unnamed facility
Barcelona, Barcelona, Spain
Response rate: Proportion of patients with reduction of viral load to < 50 copies/ml
Time frame: approximately 24 months
Duration of treatment with Fuzeon
Time frame: approximately 24 months
Time to undetectability, defined as time from initiation of treatment to first observation of viral load < 50 copies/ml
Time frame: approximately 24 months
Safety: Incidence of adverse events
Time frame: approximately 24 months
Treatment regimen: Antiretroviral drugs used
Time frame: approximately 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.